Venous thrombosis among patients with AIDS

Area of Science:

• Medical Science
• Hematology
• Infectious Diseases

Background:

• Thrombosis is an uncommon complication in patients with Acquired Immunodeficiency Syndrome (AIDS).
• The advent of highly active antiretroviral therapy (HAART) has changed the landscape of HIV/AIDS management.
• The specific risk factors for thrombosis in the HAART era remain incompletely understood.

Purpose of the Study:

• To investigate the incidence and potential risk factors for thrombosis in patients with AIDS.
• To compare thrombosis rates before and after the introduction of protease inhibitor therapy.
• To explore the association between thrombotic events and thrombophilic abnormalities in this population.

Main Methods:

• Retrospective analysis of 34 thrombotic events in 28 adult male homosexuals with AIDS over a 42-month period.
• Comparison of thrombosis rates with historical data from patients before protease inhibitor therapy.
• Evaluation of thrombophilic abnormalities including Protein C, Protein S deficiency, lupus anticoagulant, and activated protein C resistance (APCR).

Main Results:

• The rate of thrombosis was significantly higher (1.52%) during the study period compared to the pre-protease inhibitor era (0.33%) (p < 0.001).
• Deep vein thrombosis was the most common type (31 events), followed by pulmonary thromboembolism (2) and renal vein thrombosis (1).
• Protease inhibitors were implicated as a potential risk factor, independent of known thrombophilic abnormalities.

Conclusions:

• Protease inhibitors may represent a risk factor for venous thrombosis in patients with AIDS.
• The mechanism may involve abnormalities in platelets or endothelium rather than traditional thrombophilic conditions.
• Further research is needed to elucidate the exact mechanisms and guide preventative strategies.